Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Lutris Pharma logo — Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side...

Lutris Pharma

Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects

Founded 2015 Israel Israel 4 employees Grant Biotechnology, Health Care +1

General Information

Company Name Lutris Pharma
Founded Year 2015
Location Israel Israel +1
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

Get notified when Lutris Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Lutris Pharma

Lutris Pharma is a clinical stage biopharmaceutical company based in Israel. Their mission is to enhance the effectiveness and improve the quality of life for cancer patients undergoing treatment with EGFR inhibitors or radiation, where dermal toxicity often leads to reduced therapy compliance. The company’s focus is on providing novel topical therapies to mitigate these side effects. Their lead asset, LUT014, a topical B-Raf Inhibitor, is currently in phase 2 clinical trial for metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis. Since its establishment in 2015, Lutris Pharma has been operating within the Biotechnology, Health Care, and Health and Wellness industries. As of now, there is no public information available regarding their last investment or the associated investors. Lutris Pharma’s slogan summarizes their core focus: "Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects."

No funding data available for Lutris Pharma yet.

Get notified when Lutris Pharma raises funding

Lutris Pharma Alternatives & Competitors

Lutris Pharma vs
ARMO BioSciences
ARMO BioSciences United States

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, pro...

Series Unknown
1 employees
Biotechnology, Health Care
Lutris Pharma vs
miReven Pty Ltd
miReven Pty Ltd

miR-7: An anti-cancer micro RNA miReven is a biopharmaceutical company focused on developing miR-7...

3 employees
Biotechnology, Health and Wellness
Lutris Pharma vs
Glycyx
Glycyx United States

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunother...

Series A
3 employees
Biopharma, Biotechnology

FAQ About Lutris Pharma

Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects
Lutris Pharma was founded in 2015.
Lutris Pharma is headquartered in Israel.
Lutris Pharma operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Lutris Pharma has approximately 4 employees.
Top alternatives and competitors to Lutris Pharma include ARMO BioSciences, miReven Pty Ltd, Glycyx, Agennix, Shuttle Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lutris Pharma and ARMO BioSciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lutris Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy